Please login to the form below
cladribine
This page shows the latest cladribine news and features for those working in and with pharma, biotech and healthcare.
MS and cholesterol drugs picked for new UK rapid uptake push
Merck’s Mavenclad (cladribine) for treating highly active relapsing-remitting multiple sclerosis in adults - A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment
Latest news
-
Sanofi licences Principia MS drug in $805m deal
The three established players in the oral MS therapy category are also about to see additional competition from new entrant Merck KGaA, which bagged EU approval for Mavenclad (cladribine) in August.
-
Merck mulls sale of consumer health division
The news comes a few days after Merck picked up an important new approval for its pharma division in Europe, with the EMA clearing Mavenclad (cladribine) for the treatment of
-
Merck gets CHMP backing for long-delayed oral MS drug
Cladribine, which will be branded as Mavenclad, was originally rejected by the committee in 2010. ... The company thinks oral cladribine has a key differentiator from its rivals, which require daily dosing.
-
Avelumab costs peg back profit at Merck KGaA
Avelumab and other pipeline candidates such as oral MS therapy cladribine have assumed even more importance for Merck since it abandoned plans to seek approval of evofosfamide in advanced soft tissue
-
Merck's pharma unit faces tougher 2017 as fertility boost recedes
Top of that list is oral MS therapy cladribine, which was submitted for approval in the EU in June, and according to Kuhnert is proceeding through regulatory review as expected.
More from news
Approximately 2 fully matching, plus 25 partially matching documents found.
Latest appointments
-
XenoPort appoints chief medical officer
Prior to joining Biogen Idec Dr Kim was with Merck Serono, serving as medical director for the phase III programme of cladribine, which failed to impress in MS.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications
-
Salary TBC
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
Subscribe to our email news alerts
- The relevance of patient perspectives to value
- Sanofi patent case win holds off generic rivals for key cancer drug
- Leo Pharma to market AstraZeneca’s brodalumab outside Europe
- Regeneron scores positive data in phase 3 cholesterol trial
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Putting our core values into practice at the Porterhouse summer social
PMHub
Consulting at McCann Health
We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...
Latest intelligence
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
- How is the NHS Long-term Plan being put into action?
- Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
- The evolution of real-world studies
- How industry and regulators are using real-world data...
Quick links
Infographics
